| abstract |
Thiazole derivatives of formula I wherein: R1 is group III; R2 is formula II; R3 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, carboxyl, alkyl-O-CO- or aralkyl-O-CO-; R4 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; R5 and R6 are each independently hydrogen, alkyl, cycloalkyl or heteroaryl; R7 and R8 are each independently hydrogen, alkyl, cycloalkyl or aralkyl or R7 and R8 together with the Na atoms which are attached form a 5- to 8-membered heterocyclic ring which may be substituted by alkyl; R9 is hydrogen, alkyl or cycloalkyl; R 10 isaryl, aralkyl, heterocyclyl, heterocyclylalkyl, hydroxy, hydrogen or alkyl, or R 10 is carboxyl, carboxyalkyl, alkyl-O-CO-, aralkyl-O-CO-, alkyl-CO-, aralkyl-CO-, heteroarylalkyl-CO- , alkylsulfonyl, arylsulfonyl or heteroarylsulfonyl and k is 0, or R10 is an alpha amino acid linked via the amino group and l is 0 and k is 1; A is carbonyl or sulfonyl; B is hydrogen, alkyl or cycloalkyl; a and m are 0 or positive integers, a is 0 to 2, but not 0 when R1 is -NH2; b is 0 to 4; c, d, f, g, k, l and m are each, independently, 0 or 1, so that c, f and g are not simultaneously 0 and with what is 0 when f or g is 1; i is 0 or 1, so that k and l are also 0 when i is 0; e is 0 to 3; h is 0 to 5; j is 0 to 2, and the sum of e, h and j is 2 to 7; as well as its pharmaceutically usable salts and esters that inhibit the binding of adhesive proteins to the surface of different cell types and consequently influence cell-cell and cell-matrix interactions; procedures for their preparation, pharmaceutical composition containing them, intermediary compounds and their use in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastases, tumor development, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis after vascular intervention, psoriasis, arthritis, fibrosis, renal failure, as well as infections caused by viruses, bacteria or fungi. |